Timing of therapies for Down syndrome: the sooner, the better

被引:81
作者
Stagni, Fiorenza [1 ]
Giacomini, Andrea [1 ]
Guidi, Sandra [1 ]
Ciani, Elisabetta [1 ]
Bartesaghi, Renata [1 ]
机构
[1] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy
来源
FRONTIERS IN BEHAVIORAL NEUROSCIENCE | 2015年 / 9卷
关键词
Down syndrome; intellectual disability; mouse models; adult therapies; perinatal therapies; TS65DN MOUSE MODEL; SEROTONIN-REUPTAKE INHIBITORS; SYNAPTIC PLASTICITY; COGNITIVE PERFORMANCE; NEUROMORPHOLOGICAL DEFICITS; CHOLINERGIC DEGENERATION; RESTORES NEUROGENESIS; EARLY PHARMACOTHERAPY; BRAIN-DEVELOPMENT; CELL-FORMATION;
D O I
10.3389/fnbeh.2015.00265
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Intellectual disability (ID) is the unavoidable hallmark of Down syndrome (DS), with a heavy impact on public health. Accumulating evidence shows that DS is characterized by numerous neurodevelopmental alterations among which the reduction of neurogenesis, dendritic hypotrophy and connectivity alterations appear to play a particularly prominent role. Although the mechanisms whereby gene triplication impairs brain development in DS have not been fully clarified, it is theoretically possible to correct trisomy-dependent defects with targeted pharmacotherapies. This review summarizes what we know about the effects of pharmacotherapies during different life stages in mouse models of DS. Since brain alterations in DS start to be present prenatally, the prenatal period represents an optimum window of opportunity for therapeutic interventions. Importantly, recent studies clearly show that treatment during the prenatal period can rescue overall brain development and behavior and that this effect outlasts treatment cessation. Although late therapies are unlikely to exert drastic changes in the brain, they may have an impact on the hippocampus, a brain region where neurogenesis continues throughout life. Indeed, treatment at adult life stages improves or even rescues hippocampal neurogenesis and connectivity and hippocampal-dependent learning and memory, although the duration of these effects still remains, in the majority of cases, a matter of investigation. The exciting discovery that trisomy-linked brain abnormalities can be prevented with early interventions gives us reason to believe that treatments during pregnancy may rescue brain development in fetuses with DS. For this reason we deem it extremely important to expedite the discovery of additional therapies practicable in humans in order to identify the best treatment/s in terms of efficacy and paucity of side effects. Prompt achievement of this goal is the big challenge for the scientific community of researchers interested in DS.
引用
收藏
页数:18
相关论文
共 114 条
  • [41] Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
    Fernandez, Fabian
    Morishita, Wade
    Zuniga, Elizabeth
    Nguyen, James
    Blank, Martina
    Malenka, Robert C.
    Garner, Craig C.
    [J]. NATURE NEUROSCIENCE, 2007, 10 (04) : 411 - 413
  • [42] Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome
    Fortress, Ashley M.
    Hamlett, Eric D.
    Vazey, Elena M.
    Aston-Jones, Gary
    Cass, Wayne A.
    Boger, Heather A.
    Granholm, Ann-Charlotte E.
    [J]. JOURNAL OF NEUROSCIENCE, 2015, 35 (04) : 1343 - 1353
  • [43] Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design
    Furu, Kari
    Kieler, Helle
    Haglund, Bengt
    Engeland, Anders
    Selmer, Randi
    Stephansson, Olof
    Valdimarsdottir, Unnur Anna
    Zoega, Helga
    Artama, Miia
    Gissler, Mika
    Malm, Heli
    Norgaard, Mette
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [44] Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations
    Gardiner, Katheleen J.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 9 : 103 - 125
  • [45] Gozes I, 2005, CNS DRUG REV, V11, P353
  • [46] NAP and D-SAL: neuroprotection against the β amyloid peptide (1-42)
    Gozes, Illana
    Divinski, Inna
    Piltzer, Inbar
    [J]. BMC NEUROSCIENCE, 2008, 9 (Suppl 3)
  • [47] Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of Down syndrome
    Granholm, AC
    Sanders, L
    Seo, H
    Lin, L
    Ford, K
    Isacson, O
    [J]. HIPPOCAMPUS, 2003, 13 (08) : 905 - 914
  • [48] Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome
    Granholm, ACE
    Ford, KA
    Hyde, LA
    Bimonte, HA
    Hunter, CL
    Nelson, M
    Albeck, D
    Sanders, LA
    Mufson, EJ
    Crnic, LS
    [J]. PHYSIOLOGY & BEHAVIOR, 2002, 77 (2-3) : 371 - 385
  • [49] Prenatal treatment of Down syndrome: a reality?
    Guedj, Faycal
    Bianchi, Diana W.
    Delabar, Jean-Maurice
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (02) : 92 - 103
  • [50] Noninvasive prenatal testing creates an opportunity for antenatal treatment of Down syndrome
    Guedj, Faycal
    Bianchi, Diana W.
    [J]. PRENATAL DIAGNOSIS, 2013, 33 (06) : 614 - 618